Vertex appoints Daniel Brennan. Vertex Pharma stock has USD 130.4 billion value

Published on 10/21/2026 at 11:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex adds a director on October 20, 2026. Vertex Pharma stock costs EUR 455.65 on October 21, 2026, 0.04 percent below its EUR 455.85 Xetra close.

Governance and earnings calendar

Vertex expanded its board to 11 members on October 20, 2026.
Second-quarter revenue reached USD 3.33 billion, up 12.50 percent year over year.
Vertex Pharma stock trades at EUR 455.65 at 11:08 a.m. CEST at Lang & Schwarz on October 21, 2026, 0.04 percent below the Xetra close of October 20, 2026.
BofA Securities cut its target from USD 672.00 to USD 667.00 on October 12, 2026.
Third-quarter results are scheduled for November 2, 2026.

Aquarellbild der Boston-Skyline mit Segelbooten am Hafen im warmen Licht — Vertex Pharma US92532F1003 zeigt die Boston Skyline am Wasser in weicher Aquarell-Malerei-Optik mit Segelbooten, Illustration mit AI erstellt.

Vertex Pharma (ISIN US92532F1003) was trading at EUR 455.65 at Lang & Schwarz on October 21, 2026 at 11:08 a.m. CEST, 0.04 percent below the Xetra close of October 20, 2026 at EUR 455.85. The company appointed Daniel Brennan as an independent director on October 20, according to Vertex Pharmaceuticals.

Board expands to 11 members

Brennan joined the board after more than 35 years in healthcare finance, including more than 25 years at Boston Scientific Corporation. Vertex increased the board from 10 to 11 members, and Brennan also joined its Audit and Finance Committee, the October 20 company release said.

The appointment adds finance and corporate-development experience as Vertex broadens its pipeline beyond cystic fibrosis. The release said the company has approved therapies across cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly.

What does the earnings setup show?

Vertex reported second-quarter 2026 revenue of USD 3.33 billion, up 12.50 percent year over year, while diluted earnings per share came to USD 4.31, according to the standardized quarterly figures and the reported-period data carried by MarketBeat. The next quarter will test whether revenue can match the USD 3.41 billion consensus estimate.

Three recent dates and figures

On September 22, 2026, Vertex announced positive results from the Phase 2b AMPLIFIED study and completion of enrollment in the Phase 2/3 AMPLITUDE trial, as reported by FinanzNachrichten. On October 12, 2026, BofA Securities cut its price target from USD 672.00 to USD 667.00 while maintaining a Buy rating, according to Investing.com. On October 20, 2026, Brennan joined the board, which expanded to 11 members.

Next reporting date

MarketBeat estimates Vertex will report third-quarter 2026 results on November 2, 2026 after the market close, with its conference call scheduled for 4:30 p.m. ET. The same estimate calls for USD 4.77 in earnings per share and USD 3.41 billion in revenue.

Stock trades below the Xetra close

Vertex Pharma has a USD 130.4 billion market capitalization as of October 20, 2026. Its primary listing is on Nasdaq, where the finance data showed a USD 403.16 to USD 560.25 52-week range on that date. The Xetra-linked quote showed EUR 452.90 at 9:42 a.m. CEST on October 21, 2026, with a previous Xetra close of EUR 455.85.

Vertex Pharma was trading at EUR 455.65 at Lang & Schwarz on October 21, 2026 at 11:08 a.m. CEST, 0.04 percent below the Xetra close of October 20, 2026 at EUR 455.85. The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.